In this context, KRAS-G12D can be released within exosomes by ferroptotic cancer cells and taken up by macrophages through an AGER-dependent mechanism, resulting in the polarization of macrophages to an M2 phenotype and promotion of tumor growth (Dai et al., 2020a). This evidence concerns the gene KRAS and neoplasm.